real-time news and commentary for investors
Thursday, Aug 29
Becton Dickinson gets FDA approval for third drug in its BD Simplist line
- Becton, Dickinson (BDX +0.3%) subsidiary BD Rx says the FDA has approved a third drug to be offered in its new BD Simplist line of ready-to-administer prefilled generic injectables.
- The third product to launch is Ondansetron Injection, an injectable antiemetic which is used to prevent postoperative nausea and vomiting.
- The drug is currently on the FDA drug shortage list due to recent demand increases and supply issues faced by other manufacturers.